Genmab — December 2019
-
-
Det er også det Nina Shah taler om 3 min inde https://www.youtube.com/watch?v=6pbWhqladhQ&feature=youtu.be
-
Det er det vist ikke. Og det er fc-delen der bliver "silenced". Winkel skrev sidste år på q&a: You are referring to the way we have "silenced" the Fc-part of this bispecific. This has
been done in a novel manner with the intent of lessening interactions with immune
cells, resulting in less/absent non-specific activation of immune killer cells. This should
result in better safety. -
Go morgen.
-
Update on MAIA study also provided as a poster. PFS still very good 68%) at 3 years. Even with Rd it was a median of 34. Effect of risk less clear on this dataset, although lower numbers.
https://twitter.com/Rfonsi1/status/1203433426101125120 -
Rafael Fonseca MD
@Rfonsi1
·
7 t
KEY PAPER. Updated FU on POLUX presented by @kaufman_MMdoc
. After a median FU of 59 months the median PFS reported at 45 months. Interestingly TTNT not reached after 63 months. https://twitter.com/Rfonsi1/status/1203437275213967377 -
The Debate Heats Up Over Treating High Risk Smoldering Multiple Myeloma
https://paper.li/Myeloma_Doc/1310386431?read=https%3A%2F%2Fwww.myelomacrowd.org%2Fash-2019-the-debate-heats-up-over-treating-high-risk-smoldering-multiple-myeloma%2F -
-
Landgren previews pivotal ASH 2019 Myeloma data. https://www.onclive.com/conference-coverage/ash-2019/landgren-previews-pivotal-ash-2019-myeloma-data
-
-
Tak bibo. Landgren giver en god oversigt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind